CorMedix, Inc. (CRMD)
Stock Price:
$8.96 USD
-0.19 (-2.08%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
287.91M |
| Revenue (ttm) |
208,295 |
| Net Income (ttm) |
-21.24M |
| Shares Out |
32.13M |
| EPS (ttm) |
-0.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$8.96 |
| Previous Close |
$9.15 |
| Change ($) |
-0.19 |
| Change (%) |
-2.08% |
| Day's Open |
9.28 |
| Day's Range |
8.57 - 9.42 |
| Day's Volume |
536,497 |
| 52-Week Range |
2.35 - 9.42 |
More Stats
| Market Cap |
287.91M |
| Enterprise Value |
251.74M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.13M |
| Float |
n/a |
| EPS (basic) |
-0.75 |
| EPS (diluted) |
-0.79 |
| FCF / Share |
-0.67 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.00M |
| Short Ratio |
16.33 |
| Short % of Float |
n/a |
| Beta |
2.39 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1,382.21 |
| PB Ratio |
8.35 |
| Revenue |
208,295 |
| Operating Income |
-26.51M |
| Net Income |
-21.24M |
| Free Cash Flow |
-19.96M |
| Net Cash |
36.17M |
| Net Cash / Share |
1.13 |
| Gross Margin |
-43.19% |
| Operating Margin |
-12,728.07% |
| Profit Margin |
-10,199.40% |
| FCF Margin |
-9,584.41% |
| ROA |
-44.94% |
| ROE |
-67.25% |
| ROIC |
-524.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$15.75*
(75.78% upside)
Low
10.0
Current: $8.96
High
22.0
Target: 15.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.28 | 0.43 | 0.33 | 0.22 | 0.21 | 0.19 | - | - | - | - |
| Revenue Growth | -34.09% | 30.51% | 46.95% | 6.65% | 11.02% | 9358.97% | - | - | - | - |
| Gross Profit | -0.09 | 0.03 | 0.21 | -0.14 | -0.11 | -0.26 | -0.20 | - | - | - |
| Operating Income | -21.01 | -26.86 | -32.92 | -24.76 | -16.65 | -8.90 | -4.92 | -3.00 | -7.21 | -8.51 |
| Net Income | -16.43 | -26.83 | -33.01 | -24.64 | -18.19 | -20.45 | -9.13 | -3.38 | -6.67 | -10.91 |
| Shares Outstanding | 24.15 | 17.82 | 11.03 | 7.59 | 6.27 | 4.29 | 2.76 | 2.28 | 2.28 | 1.89 |
| Earnings Per Share | -1.80 | -1.51 | -3.00 | -3.25 | -2.90 | -4.80 | -3.45 | -1.50 | -2.90 | -5.75 |
| Operating Cash Flow | -15.05 | -23.70 | -28.59 | -22.27 | -12.53 | -6.32 | -3.62 | -2.28 | -6.30 | -3.67 |
| Capital Expenditures | -0.04 | -0.05 | -0.15 | -0.06 | -0.02 | -0.03 | -0.04 | - | - | -0.01 |
| Free Cash Flow | -15.09 | -23.75 | -28.74 | -22.32 | -12.54 | -6.35 | -3.65 | -2.28 | -6.30 | -3.68 |
| Cash & Equivalents | 28.51 | 17.80 | 12.16 | 20.34 | 35.56 | 4.34 | 2.59 | 0.84 | 1.99 | 8.28 |
| Total Debt | - | 6.13 | - | - | - | - | - | 0.27 | - | - |
| Net Cash / Debt | 28.51 | 11.67 | 12.16 | 20.34 | 35.56 | 4.34 | 2.59 | 0.57 | 1.99 | 8.28 |
| Assets | 29.48 | 18.83 | 13.45 | 21.91 | 37.10 | 5.10 | 2.97 | 1.15 | 2.56 | 8.85 |
| Liabilities | 5.83 | 13.89 | 6.26 | 4.09 | 3.09 | 1.46 | 6.99 | 1.49 | 1.22 | 1.59 |
| Book Value | 23.65 | 4.93 | 7.19 | 17.81 | 34.01 | 3.63 | -4.02 | -0.34 | 1.33 | 7.26 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CorMedix, Inc. |
| Country |
United States |
| Employees |
30 |
| CEO |
Mohammed Khoso Baluch |
Stock Information
| Ticker Symbol |
CRMD |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: CRMD |
| IPO Date |
March 25, 2010 |
Description
CorMedix, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.